[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 143,829
  • Shares Outstanding, K 36,229
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -28,620 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.14
  • Price/Sales 117.71
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 164.30% (-5.03%)
  • Historical Volatility 112.10%
  • IV Percentile 31%
  • IV Rank 20.63%
  • IV High 734.57% on 02/13/26
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 26) 0.35 (8.78%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 377
  • Volume Avg (30-Day) 478
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 15,563
  • Open Int (30-Day) 14,670
  • Expected Range 3.62 to 4.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.05
  • Low Estimate $-0.13
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) +90.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.86 +38.81%
on 05/20/26
5.05 -21.46%
on 06/02/26
+0.86 (+27.45%)
since 05/18/26
3-Month
1.72 +130.81%
on 03/23/26
5.05 -21.46%
on 06/02/26
+2.07 (+108.95%)
since 03/18/26
52-Week
1.62 +145.06%
on 03/09/26
5.05 -21.46%
on 06/02/26
+0.74 (+22.91%)
since 06/18/25

Most Recent Stories

More News
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Featured Interviews Include Aeries Technology (NASDAQ: AERT), Virtuix Holdings (NASDAQ: VTIX), and EmpowerLit; Sponsored Programming Supported by DataVault AI (NASDAQ: DVLT), IGC Pharma (NYSE American:...

IGC : 0.2749 (-0.29%)
VTIX : 3.66 (+5.17%)
AERT : 7.22 (+3.29%)
MDCX : 0.4575 (+30.08%)
NRXP : 3.97 (-0.25%)
DVLT : 0.4065 (+0.99%)
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

WILMINGTON, Del., June 04, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals Q1 Earnings Call Highlights

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free...

NRXP : 3.97 (-0.25%)
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026,...

NRXP : 3.97 (-0.25%)
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma

The show broadcasts as sponsored programming featuring TV commercials from IGC Pharma, Inc. (NYSE American:IGC), NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Medicus Pharma Ltd. (NASDAQ:MDCX), and DataVault...

CAST : 8.07 (+56.70%)
SDST : 1.8700 (+3.31%)
IGC : 0.2749 (-0.29%)
VTIX : 3.66 (+5.17%)
MDCX : 0.4575 (+30.08%)
NRXP : 3.97 (-0.25%)
DVLT : 0.4065 (+0.99%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 4.30
2nd Resistance Point 4.22
1st Resistance Point 4.10
Last Price 3.97
1st Support Level 3.90
2nd Support Level 3.82
3rd Support Level 3.70

See More

52-Week High 5.05
Last Price 3.97
Fibonacci 61.8% 3.74
Fibonacci 50% 3.34
Fibonacci 38.2% 2.93
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.